This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Van den Brande, P. Articles by Maurel, A. Search for Related Content PubMed PubMed Citation Articles by Van den Brande, P. Articles by Maurel, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Foot Health Social Bookmarking                         What's this?

A Placebo-Controlled Study of the Effects of Intravenous Buflomedil on Foot Skin Microcirculation in Patients with Severe Intermittent Claudication

Department of Vascular Surgery Academic Hospital Vrije Universiteit Brussel Laarbeeklaan 101 B-1090 Brussels Belgium.

A. Maurel, MD

Laboratoire L. Lafon, F-94700 Maisons-Alfort, France.

Buflomedil hydrochloride (Buflomedil), a vasoactive drug, has been proven to improve pain-free walking distance in patients with peripheral arterial occlusive disease stage II of the lower extremities.

In the present double-blind, randomized study, resting skin flux motion activity and skin flux response to a local heat stress at the hallux were assessed by laser Doppler fluxmetry (LDF) in claudicants. Twenty of 39 enrolled patients with severe intermittent claudication received a daily intravenous dose of 400 mg Buflomedil, and the other 19 patients received 0.9% NaCl as placebo over a 5-day period.

Before treatment mean LDF skin resting flux, flux frequency, and flux amplitude were 2 ±0.8 Arbitrary Units (AU), 8.4 ±0.5 cycles per minute (c/min), and 0.12 ±0.01 AU, respectively in the Buflomedil group, and 2.3 ±0.3 AU, 8.7 ±0.7 c/min, and 0.13 ±0.02 AU in the placebo group (NS). Also the response to heat stress was identical in both groups: a slow initial increase of skin flux, followed by a reflex reduction, with a maximal initial flux increase to 138 ± 12% of the resting value in the Buflomedil group, and 155 ± 16% in the placebo group (NS). (continued on next page)

After 5 days of treatment the mean LDF skin resting flux, flux frequency, and flux amplitude were unchanged in both patient groups. The response to heating on the contrary was dramatically enhanced in the Buflomedil group (226 ±33%), against that in the placebo group, which remained unchanged (144 ±13%) after 3 minutes (P<0.05), while after reflex reduction the flux in the Buflomedil group remained stable at 200% of resting value during further heating and was only approximately 140% in the placebo group (P<0.05).

It is concluded that Buflomedil, administered in a daily intravenous dose of 400 mg, does not alter the mean LDF skin flux and flux motion at the hallux in claudicants in resting conditions. Local skin heating on the contrary provokes a significant LDF monitored skin flux increase, suggesting an improved capacity of cutaneous microvessel perfusion in stressed conditions.

Angiology, Vol. 49, No. 2, 105-114 (1998)
DOI: 10.1177/000331979804900203


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?